Colin Bristow
Stock Analyst at UBS
(2.26)
# 1,463
Out of 4,412 analysts
64
Total ratings
42.86%
Success rate
-2.26%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,090 → $1,099 | $883.20 | +24.43% | 1 | Apr 17, 2024 | |
| AMGN Amgen | Maintains: Neutral | $314 → $284 | $269.98 | +5.19% | 4 | Apr 17, 2024 | |
| BIIB Biogen | Maintains: Neutral | $250 → $214 | $208.90 | +2.44% | 9 | Apr 17, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $81 → $75 | $65.42 | +14.64% | 2 | Apr 17, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $498 → $466 | $397.48 | +17.24% | 11 | Apr 17, 2024 | |
| ENGN enGene Holdings | Initiates: Buy | $37 | $15.50 | +138.71% | 1 | Mar 28, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $56 → $54 | $21.98 | +145.68% | 2 | Mar 1, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $164 → $167 | $128.77 | +29.69% | 5 | Mar 1, 2024 | |
| BTAI BioXcel Therapeutics | Downgrades: Neutral | $9 → $4 | $2.63 | +52.09% | 3 | Feb 21, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $135 → $148 | $131.20 | +12.80% | 3 | Feb 2, 2024 | |
| PFE Pfizer | Maintains: Neutral | $34 → $27 | $25.40 | +6.30% | 4 | Dec 14, 2023 | |
| IMVT Immunovant | Maintains: Buy | $55 → $56 | $27.17 | +106.11% | 4 | Dec 1, 2023 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $29 → $27 | $16.86 | +60.14% | 3 | Oct 4, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $428 → $420 | $733.51 | -42.74% | 1 | Dec 15, 2022 | |
| OMER Omeros | Downgrades: Neutral | $12 → $2 | $3.15 | -36.51% | 2 | Dec 8, 2022 | |
| PROK ProKidney | Initiates: Buy | $18 | $2.12 | +749.06% | 1 | Oct 18, 2022 | |
| ABBV AbbVie | Maintains: Neutral | $154 → $146 | $159.62 | -8.53% | 2 | Aug 1, 2022 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $73 → $75 | $44.85 | +67.22% | 1 | Jul 28, 2022 | |
| CCCC C4 Therapeutics | Maintains: Buy | $64 → $26 | $6.17 | +321.39% | 1 | Apr 18, 2022 | |
| CADL Candel Therapeutics | Initiates: Buy | n/a | $6.39 | - | 1 | Aug 23, 2021 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | n/a | $3.17 | - | 1 | Jul 26, 2021 | |
| MTEM Molecular Templates | Initiates: Neutral | n/a | $1.71 | - | 1 | Feb 1, 2021 | |
| PTCT PTC Therapeutics | Initiates: Neutral | n/a | $28.57 | - | 1 | Oct 28, 2020 |
Regeneron Pharmaceuticals
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $883.20
Upside: +24.43%
Amgen
Apr 17, 2024
Maintains: Neutral
Price Target: $314 → $284
Current: $269.98
Upside: +5.19%
Biogen
Apr 17, 2024
Maintains: Neutral
Price Target: $250 → $214
Current: $208.90
Upside: +2.44%
Gilead Sciences
Apr 17, 2024
Maintains: Neutral
Price Target: $81 → $75
Current: $65.42
Upside: +14.64%
Vertex Pharmaceuticals
Apr 17, 2024
Maintains: Buy
Price Target: $498 → $466
Current: $397.48
Upside: +17.24%
enGene Holdings
Mar 28, 2024
Initiates: Buy
Price Target: $37
Current: $15.50
Upside: +138.71%
Rocket Pharmaceuticals
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $21.98
Upside: +145.68%
Sarepta Therapeutics
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $128.77
Upside: +29.69%
BioXcel Therapeutics
Feb 21, 2024
Downgrades: Neutral
Price Target: $9 → $4
Current: $2.63
Upside: +52.09%
Merck & Co.
Feb 2, 2024
Maintains: Buy
Price Target: $135 → $148
Current: $131.20
Upside: +12.80%
Pfizer
Dec 14, 2023
Maintains: Neutral
Price Target: $34 → $27
Current: $25.40
Upside: +6.30%
Immunovant
Dec 1, 2023
Maintains: Buy
Price Target: $55 → $56
Current: $27.17
Upside: +106.11%
ALX Oncology Holdings
Oct 4, 2023
Maintains: Buy
Price Target: $29 → $27
Current: $16.86
Upside: +60.14%
Eli Lilly
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $733.51
Upside: -42.74%
Omeros
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.15
Upside: -36.51%
ProKidney
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.12
Upside: +749.06%
AbbVie
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $159.62
Upside: -8.53%
Bristol-Myers Squibb Company
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $44.85
Upside: +67.22%
C4 Therapeutics
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $6.17
Upside: +321.39%
Candel Therapeutics
Aug 23, 2021
Initiates: Buy
Price Target: n/a
Current: $6.39
Upside: -
Acumen Pharmaceuticals
Jul 26, 2021
Initiates: Buy
Price Target: n/a
Current: $3.17
Upside: -
Molecular Templates
Feb 1, 2021
Initiates: Neutral
Price Target: n/a
Current: $1.71
Upside: -
PTC Therapeutics
Oct 28, 2020
Initiates: Neutral
Price Target: n/a
Current: $28.57
Upside: -